David Kuter, MD, DPhil

• Myelofibrosis
• Chronic myeloid leukemia

My basic science research involves hematopoiesis. We investigate the mechanism of apoptosis in megakaryocytes and platelets. We also assess the molecular mechanism by which thrombopoietin is regulated and interacts with its receptor, c-Mpl. My clinical research is focussed on thrombosis/hemostasis and hematopoietic growth factors. We are studying the use of thrombopoietin in ITP, the use of Novel Erythropoiesis-Stimulating Protein (NESP) in anemic chemotherapy patients and the role of thrombopoietin in preventing chemotherapy-induced thrombocytopenia. We are studying the thrombophilia of malignancy and the role of low-molecular weight heparins in its treatment and in the prevention of catheter-related thrombosis.